logo

Biogen Inc. (BIIB)



Trade BIIB now with
  Date
  Headline
10/22/2019 7:06:20 AM Biogen Q3 EPS $8.39; Non-GAAP EPS $9.17
10/22/2019 6:37:26 AM Biogen Plans To Submit BLA For Aducanumab In Early 2020
10/22/2019 6:36:02 AM Biogen Plans To Pursue Regulatory Approval For Aducanumab
10/3/2019 8:01:34 AM Biogen Canada Announce Positive Results From The NURTURE Study
10/1/2019 8:14:12 AM Biogen: Michael Ehlers, EVP, Research And Development, To Leave
9/13/2019 8:02:31 AM Eisai And Biogen To Discontinue Phase III Clinical Studies Of BACE Inhibitor Elenbecestat In Early Alzheimer's Disease
7/30/2019 8:01:19 AM Alkermes Announces Positive Topline Results From EVOLVE-MS-2 Phase 3 Study Of Diroximel Fumarate
7/23/2019 7:55:49 AM Biogen Inc. (BIIB) Has Raised Its FY19 Revenue Estimate To $14.0 - $14.2 Bln From $13.6 - $13.8 Bln
7/23/2019 7:55:02 AM Biogen Inc. (BIIB) Has Raised Its FY19 EPS Estimate To 31.50 - 32.30 From 28.00 - 29.00
7/23/2019 6:44:54 AM Biogen Q2 GAAP EPS $7.85 Vs $4.18 Last Year
7/1/2019 7:33:05 AM Biogen Announces New Results From NURTURE Study
6/13/2019 6:01:51 AM Biogen Canada Says Ontario Grants Broader Access To SPINRAZA For Patients Living With Spinal Muscular Atrophy
  
 
>